Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276942 | 1.00 | CYP3A4 (0.48) | CYP3A4MAPTADRA1AMAOATSHR | |
| SCHEMBL7936406 | 1.00 | CYP3A4 (0.48) | CYP3A4MAPTADRA1AMAOATSHR | |
| Hydrochloric Acid SCHEMBL15664148 | 0.98 | CYP3A4 (0.46) | CYP3A4MAPTADRA1AMAOATSHR | |
| SCHEMBL28046681 | 0.80 | CA1 (0.54) | CYP3A4MAPTMAOATSHRRAD52 | |
| SCHEMBL355553 | 0.80 | CA1 (0.54) | CYP3A4MAPTMAOATSHRRAD52 | |
| Hydrochloric Acid SCHEMBL17910635 | 0.79 | CA1 (0.53) | CYP3A4MAOATSHRRAD52CA1 | |
| SCHEMBL1748257 | 0.77 | CHRNA7 (0.48) | CYP3A4MAPTMAOATSHRRAD52 | |
| SCHEMBL4565692 | 0.77 | ACHE (0.56) | CYP3A4MAPTMAOATSHRRAD52 | |
| SCHEMBL3159301 | 0.77 | ACHE (0.56) | CYP3A4MAPTMAOATSHRRAD52 | |
| Hydrochloric Acid SCHEMBL10557112 | 0.76 | DRD5 (0.46) | CYP3A4MAPTMAOATSHRRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166004-B1 | New method for resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile and their application to the synthesis of ivabradine | SERVIER LAB (FR) | 2010-10-06 | — | — | EP | disclosed |
| EP-2166004-A1 | New method for resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile and their application to the synthesis of ivabradine | Les Laboratoires Servier (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010023383-A1 | NOVEL METHOD FOR RESOLVING THE ENANTIOMERS OF (3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-13,5-TRIEN-7-YL)NITRILE AND USE IN THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056778-A1 | Process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl) nitrile and application in the synthesis of ivabradine | LES LABORATOIRES SERVIER (FR) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056778-A1 | Process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl) nitrile and application in the synthesis of ivabradine | HCN4, NISCH, SCN5A | CYP3A4 9/4885MAPT 4569/4885ADRA1A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.